Prognostic value of vascular endothelial growth factor receptor 1 and class III β-tubulin in survival for non-metastatic rectal cancer
Xiang-Quan Kong, Yun-Xia Huang, Jin-Luan Li, Xue-Qing Zhang, Li-Rui Tang, Jun-Xin Wu, Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, Fujian Province, China
Qing-Qin Peng, Department of Radiation Oncology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou 362000, Fujian Province, China
Author contributions: All authors helped to perform the research; Kong XQ wrote the manuscript and performed procedures; Huang YX wrote the manuscript and performed data analysis; Li JL contributed to writing the manuscript and drafting conception; Zhang XQ, Peng QQ and Tang LR contributed to writing the manuscript and data analysis; Wu JX contributed to writing the manuscript, drafting conception and design.
Supported by Fujian Province Natural Science Foundation, Nos. 2016J01437, 2017J01260 and 2018J01266; the Fujian Medical Innovation Project, No. 2015-CX-8; the Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (2017 Open Project-9), Joint Funds for the innovation of science and Technology, Fujian Province, No. 2017Y9074.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Fujian Cancer Hospital.
Informed consent statement: Patients were not required to give informed consent to the study due to the retrospective nature of the study involving the review of patient medical records and tumor specimens.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jun-Xin Wu, PhD, Attending Doctor, Professor, Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, 420 Fuma Rd, Jinan District, Fuzhou 350014, Fujian Province, China. email@example.com
Received: June 2, 2018
Peer-review started: June 2, 2018
First decision: July 10, 2018
Revised: July 17, 2018
Accepted: August 26, 2018
Article in press: August 26, 2018
Published online: October 15, 2018